Close Menu

A high density of CD8 T cells, along with increased activity of a specific immune pathway, may help identify which metastatic prostate cancer patients will respond to immune checkpoint blockade (ICB) therapy, according to a report appearing in Science Translational Medicine. ICB has shown promise in treating advanced cancers but tends to be most effective against tumors with high mutational burden since there are neoantigens available for targeting by reinvigorated T cells.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Politico reports that the NYPD DNA database has grown since it announced it would be removing profiles from it.

Forbes reports that a structural biology lab at Oxford University studying the coronavirus was hacked.

Science reports that a Dutch research funding agency is combating a ransomware attack.

In Science this week: set of 64 haplotype assemblies from 32 individuals, and more.